Back to discover
Drug

Ceftriaxone

Regulatory activity · MHRA
Emerging researchLate-stage development

Also known as Rocephin, Ceftriaxona, CefTRIAXone Sodium, Ceftriaxonum.

1
Research papers
9
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Clinical trial2026-02-01Primary completion · ClinicalTrials.gov

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy

Clinical trial2026-01-27Results expected Q4 2026 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ceftriaxone
Aliases & brands
RocephinCeftriaxonaCefTRIAXone SodiumCeftriaxonum
RxNorm CUI
2193
ChEMBL ID
CHEMBL161
UNII
75J73V1629
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2014-12-11Safety communicationSafety
Drug Safety Update: Ceftriaxone (rocephin): incompatible with solutions containing calcium
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

98 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
98
registered trials across all phases
LATEST COMPLETION 2026
9
Active studies
8
Recruiting
73
Late-stage (III+)
58
Completed
31
Discontinued
PHASE DISTRIBUTIONn = 98
Early Phase 11Phase 14Phase 1 / 23Phase 217Phase 2 / 35Phase 326Phase 428Phase N / A14

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Current medical research and opinion1
Leading researchers
  • Battikha J1
  • Harb G1
  • Lebel F1
  • Thackara JW1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.